I-Mab Future Growth
Future criteria checks 2/6
I-Mab is forecast to grow earnings and revenue by 0.1% and 29.3% per annum respectively while EPS is expected to grow by 12% per annum.
Key information
0.1%
Earnings growth rate
12.0%
EPS growth rate
Biotechs earnings growth | 24.2% |
Revenue growth rate | 29.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 06 Jun 2024 |
Recent future growth updates
Recent updates
I-Mab: Trading Below Net Cash With Multiple Upside Options
Feb 18We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Sep 27I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Sep 13I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
Aug 30I-Mab and senior executives may buy $40M worth of shares; stock up 10%
Aug 23Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 20I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
Jul 22I-Mab Valuation Offers A Biotech Investment Opportunity
Jun 23Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
May 06Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
Apr 01I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Jan 03I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
Oct 14Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Jul 02I-Mab adds gastrointestinal oncology expert Andrew Zhu to Scientific Advisory Board
Jun 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 7 | -1,220 | -637 | N/A | 3 |
12/31/2025 | 5 | -1,060 | -584 | N/A | 4 |
12/31/2024 | 5 | -1,038 | -548 | N/A | 4 |
12/31/2023 | 28 | -1,466 | -1,316 | -1,305 | N/A |
9/30/2023 | -113 | -1,849 | N/A | N/A | N/A |
6/30/2023 | -254 | -2,138 | N/A | N/A | N/A |
3/31/2023 | -238 | -2,275 | N/A | N/A | N/A |
12/31/2022 | -222 | -2,507 | -1,149 | -1,103 | N/A |
9/30/2022 | -50 | -2,405 | N/A | N/A | N/A |
6/30/2022 | 122 | -2,302 | -1,146 | -1,102 | N/A |
3/31/2022 | 105 | -2,317 | -1,075 | -1,037 | N/A |
12/31/2021 | 88 | -2,332 | -1,003 | -973 | N/A |
9/30/2021 | 1,596 | -662 | 288 | 308 | N/A |
6/30/2021 | 1,560 | -23 | 329 | 341 | N/A |
3/31/2021 | 1,552 | 224 | 377 | 387 | N/A |
12/31/2020 | 1,543 | 471 | 426 | 434 | N/A |
9/30/2020 | N/A | -952 | -811 | -799 | N/A |
6/30/2020 | 15 | -1,211 | -839 | -829 | N/A |
3/31/2020 | 23 | -1,348 | -860 | -848 | N/A |
12/31/2019 | 30 | -1,485 | -880 | -868 | N/A |
9/30/2019 | 40 | -1,227 | -790 | -778 | N/A |
6/30/2019 | 47 | -1,093 | -618 | -606 | N/A |
3/31/2019 | 51 | -748 | -457 | -443 | N/A |
12/31/2018 | 54 | -403 | -295 | -281 | N/A |
12/31/2017 | 12 | -298 | -272 | -252 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMAB's revenue (29.3% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: IMAB's revenue (29.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMAB's Return on Equity is forecast to be high in 3 years time